Jia Huijun, Gong Yifan, Wei Hongyu, Zhao Chengguang, Zang Qiwei, Liew Constance Sat Lin
Cardiothoracic Department, Jiangsu Province (Suqian) Hospital, Suqian, Jiangsu, China.
Faculty of Medicine and Health Science, University Malaysia Sabah, 88200, Kota Kinabalu, Malaysia.
Discov Oncol. 2025 Jun 11;16(1):1054. doi: 10.1007/s12672-025-02595-z.
This study systematically analyzes the research landscape of lung cancer and pulmonary microbiota from 2015 to 2024 using bibliometric methods.
The Web of Science Core Collection provided data analyzed to uncover key contributors, pivotal research hotspots, and evolving trends.
Results revealed a significant shift in focus from infections and inflammation to immunotherapy, microbial biomarkers, and immune response modulation, reflecting interplay between pulmonary microbiota and immune regulation in tumorigenesis. Major contributors, including China and the United States, along with leading journals, have driven progress in this interdisciplinary field, highlighting microbial imbalance's involvement in tumorigenesis and immune modulation. The findings underscore the potential of pulmonary microbiota as therapeutic targets and immune modulators, particularly for improving immunotherapy outcomes.
This study provides a comprehensive overview of the field, offering insights into its current status and future directions, and establishes a foundation for further exploration of personalized medicine and immune-centered therapies.
本研究采用文献计量学方法系统分析了2015年至2024年肺癌与肺部微生物群的研究概况。
利用科学网核心合集提供的数据进行分析，以揭示关键贡献者、关键研究热点和发展趋势。
结果显示研究重点从感染和炎症显著转向免疫治疗、微生物生物标志物和免疫反应调节，反映了肺部微生物群与肿瘤发生过程中免疫调节之间的相互作用。包括中国和美国在内的主要贡献者以及领先期刊推动了这一跨学科领域的进展，突出了微生物失衡在肿瘤发生和免疫调节中的作用。研究结果强调了肺部微生物群作为治疗靶点和免疫调节剂的潜力，特别是在改善免疫治疗效果方面。
本研究全面概述了该领域，深入了解其现状和未来方向，并为进一步探索个性化医学和以免疫为中心的治疗方法奠定了基础。
